For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenue | 0 | 1,322,410 | ||
| Research and development | 34,352,332 | 30,251,667 | ||
| General and administrative | 14,601,031 | 13,981,263 | ||
| Total operating expenses | 48,953,363 | 44,232,930 | ||
| Loss from operations | -48,953,363 | -42,910,520 | ||
| Changes in fair value of warrant liabilities | -62,754,186 | -5,385,009 | ||
| Interest expense | 240,664 | 318,401 | ||
| Interest income | 1,432,032 | 1,285,998 | ||
| Other income | 3,133,784 | 2,452,605 | ||
| Warrant issuance expense | 4,852,292 | - | ||
| Total other income | 62,227,046 | 8,805,211 | ||
| Net income (loss) | 13,273,683 | -34,105,309 | ||
| Unrealized gain, change in fair value of available-for-sale securities, net of tax | 185,464 | - | ||
| Foreign currency translation gain (loss) | 136,456 | - | ||
| Total comprehensive income (loss) | 13,595,603 | - | ||
| Basic EPS | 0.22 | -3.68 | ||
| Diluted EPS | -0.79 | -3.68 | ||
| Basic Average Shares | 19,311,798 | 9,261,918 | ||
| Diluted Average Shares | 61,340,193 | 9,261,918 | ||
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)